Objective: To establish a human xenotransplantation model of prostate cancer and evaluate the anti-tumor effect of different treatment schemes
Methods: Human fresh prostate cancer specimens were mixed with matrix glue and implanted subcutaneously into nude mice supplemented with exogenous androgen. Tumor growth was monitored continuously, and its fidelity was evaluated and passed on continuously; The tumor bearing mice were divided into four groups: docetaxel group, castration group, docetaxel combined castration group and control group. During the treatment, the tumor volume and mouse weight changes were measured. After the treatment, the total prostate specific antigen (tPSA) concentration in serum and histopathological changes were detected to evaluate the treatment effect
Results: The PDX model of prostate cancer was successfully established, including hormone sensitive (D17225) and castration resistant (C40019) tumors. Pathological analysis showed that the transplanted tumors kept the main characteristics of the patients' primary tumors; Histopathology and serum tPSA detection showed that the docetaxel group and docetaxel combined castration group showed good therapeutic effect in D17225 model, and the latter had more obvious tumor inhibition effect
Conclusion: The PDX model of prostate cancer has been successfully established and passed on stably. Docetaxel alone or combined with castration has significant therapeutic effect on hormone sensitive (D17225) prostate cancer PDX model